IP Library Granted Patent US 8,501,818
Granted Patent B2
US 8,501,818 · App. 12/687,605 · Granted Aug 6, 2013

Stabilized compositions of alkylating agents and methods of using same

Inventors: Robert Alonso (Rye, NH); Martin Stogniew (Blue Bell, PA); Peter A. Crooks (Nicholasville, KY); Mark A. Pimley (Westchester, PA); David R. Worthen (Wakefield, RI)
Assignee: Ceptaris Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,818
App. No.
12/687,605
Granted
Aug 6, 2013
Kind
B2
Abstract

Provided are stable compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions.

Claims (27)

1. A topical composition comprising: (a) an effective amount of bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically acceptable excipient comprising a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 1-6 carbon atoms, wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 3 months to about 3 years at a temperature of about −20° C. to about 8° C.

2. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 3 months to about 3 years at a temperature of about 2° C. to about 8° C.

3. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 6 months to about 3 years at a temperature of about 2° C. to about 8° C.

4. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 12 months to about 3 years at a temperature of about 2° C. to about 8° C.

5. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 24 months to about 3 years at a temperature of about 2° C. to about 8° C.

6. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 3 months to about 3 years at a temperature of about −20° C. to about −10° C.

7. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 6 months to about 3 years at a temperature of about −20° C. to about −10° C.

8. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 12 months to about 3 years at a temperature of about −20° C. to about −10° C.

9. The composition of claim 1 , wherein at least about 90% of the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt or solvate thereof is present in the composition after storage for at least about 24 months to about 3 years at a temperature of about −20° C. to about −10° C.

10. A topical composition comprising: (a) an effective amount of bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically acceptable excipient comprising a compound of the formula HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is a linear alkyl group having 1-6 carbon atoms, wherein the composition contains less than about 10% by weight of nitrogen mustard degradation product after storage for about 3 months to about 3 years at a temperature of about −20° C. to about 8° C.

11. The composition of claim 10 , wherein the nitrogen mustard degradation product is a half-mustard.

12. The composition of claim 11 , wherein the half-mustard has the following structure (DP-B):

wherein:

E is —O—, —NH—, —S—; —OC(O)CH(CH 3 )OC(O)CH(CH 3 )-; —OCH(CH 3 )C(O)OCH(CH 3 )-; or —O(CH 2 ) 20 (CH 2 ) 20 -; and

R 80 is a linear or branched alkyl group having 1-12 carbon atoms, —COOH, or —OH.

13. The composition of claim 10 , wherein the nitrogen mustard degradation product is

14. The composition of claim 10 , wherein the nitrogen mustard degradation product is

15. The composition of claim 10 , wherein the nitrogen mustard degradation product is

16. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 3 months to about 3 years at a temperature of about 2° C. to about 8° C.

17. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 6 months to about 3 years at a temperature of about 2° C. to about 8° C.

18. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 12 months to about 3 years at a temperature of about 2° C. to about 8° C.

19. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 24 months to about 3 years at a temperature of about 2° C. to about 8° C.

20. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 3 months to about 3 years at a temperature of about −20° C. to about −10° C.

21. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 6 months to about 3 years at a temperature of about −20° C. to about −10° C.

22. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 12 months to about 3 years at a temperature of about −20° C. to about −10° C.

23. The composition of claim 10 , wherein the composition contains less than about 10% by weight of the nitrogen mustard degradation product after storage for at least about 24 months to about 3 years at a temperature of about −20° C. to about −10° C.

24. The composition of claim 10 , wherein the nitrogen mustard degradation product is:

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2023
From: HAMILTON SA LLC
To: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 064961/0567 →
SECURITY INTEREST Recorded Dec 30, 2022
From: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
To: HAMILTON SA LLC
Reel/Frame 062254/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2020
From: ACTELION PHARMACEUTICALS LTD
To: HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 051542/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2014
From: CEPTARIS THERAPEUTICS, INC.
To: ACTELION PHARMACEUTICALS, LTD.
Reel/Frame 031896/0320 →
CHANGE OF NAME Recorded Feb 24, 2012
From: YAUPON THERAPEUTICS, INC.
To: CEPTARIS THERAPEUTICS, INC.
Reel/Frame 027757/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2010
From: ALONSO, ROBERT; STOGNIEW, MARTIN; CROOKS, PETER A.; PIMLEY, MARK A.; LESSIN, STUART R.; WALKER, BARRY R.; WORTHEN, DAVID R.
To: YAUPON THERAPEUTICS, INC.
Reel/Frame 024010/0935 →
Continuity (6)
Continuation In Part 11369305 · Mar 7, 2006
Continuation In Part 12401812 · Mar 11, 2009
Provisional Application 60661356 · Mar 14, 2005
Provisional Application 60751128 · Dec 16, 2005
Provisional Application 61039840 · Mar 27, 2008
Related Publication 20100152300A1 · Jun 17, 2010